Demineralized bone matrix (DBM)

Demineralized bone matrix (DBM) is a bioactive allograft material produced by the acid extraction of minerals from donor bone, leaving behind an organic matrix rich in Type I collagen and non-collagenous proteins [2, 3, 6]. It is widely used in clinical settings as a bone graft substitute or extender due to its dual properties of osteoconduction and osteoinduction [4, 13]. The collagenous framework provides a physical scaffold that supports the migration and attachment of host cells and the development of new vasculature, while the preserved growth factors, such as bone morphogenetic proteins (BMPs), actively signal for the recruitment and differentiation of mesenchymal stem cells into bone-forming osteoblasts [5, 14]. Clinically, DBM is utilized in a wide range of procedures, including spinal fusion, the repair of large bone defects, and dental applications [4, 13]. While DBM is not a traditional molecular drug target such as a receptor or enzyme, it serves as a therapeutic agent and a versatile delivery vehicle for exogenous drugs like recombinant BMPs or platelet-derived growth factors to enhance localized healing [7, 9]. Safety considerations include the potential for disease transmission from donor tissue and variability in the osteoinductive potency of different commercial preparations [10, 13]. Despite these challenges, DBM remains a cornerstone of regenerative medicine in orthopedics due to its ability to facilitate natural bone remodeling and fusion [5, 11].

Other names

Demineralized boneDFDBADemineralized Freeze-Dried Bone AllograftAlloMatrixGrafton

Demineralized bone matrix functions through osteoinduction, where endogenous growth factors like bone morphogenetic proteins (BMPs) stimulate the differentiation of mesenchymal stem cells into osteoblasts, and osteoconduction, where the collagenous matrix serves as a scaffold for host cell infiltration and new bone formation [1, 6, 14].